Table 2.
Comparisons of characteristics between the bevacizumab group and the observation group.
| Characteristics | Bevacizumab group (n = 33) |
Observation group (n = 16) |
P-value |
|---|---|---|---|
| Age, years | 77.2 ± 8.6 | 79.7 ± 7.5 | 0.601† |
| Male:female | 9 (27.3%):24 (72.7%) | 3 (18.8%):13 (81.3%) | 0.726‡ |
| Diabetes mellitus | 2 (6.1%) | 1 (6.3%) | 1.000‡ |
| Hypertension | 26 (78.8%) | 7 (43.8%) | 0.023†† |
| Use of anticoagulants | 9 (27.3%) | 3 (18.8%) | 0.726‡ |
| Blood pressure, mmHg | |||
| Systolic | 139.1 ± 15.0 | 138.9 ± 17.9 | 0.847† |
| Diastolic | 76.1 ± 11.4 | 79.7 ± 14.7 | 0.171† |
| Extent of hemorrhage, disc areas | 7.9 ± 4.9 | 11.2 ± 5.4 | 0.039† |
| Presence of intraretinal hemorrhagea | 13 (40.6%) | 6 (42.9%) | 1.000†† |
| Presence of submacular hemorrhage | 16 (48.5%) | 12 (75.0%) | 0.079†† |
| Follow-up period, months | 25.4 ± 16.2 | 23.4 ± 13.8 | 0.543† |
Data are presented as mean ± standard deviation or number (%) where applicable.
aAnalysis was performed based on 46 patients (32 in the bevacizumab group and 14 in the observation group), excluding three patients in whom the presence of intraretinal hemorrhage was undeterminable.
†Statistical analysis was performed using Mann–Whitney U test.
‡Statistical analysis was performed using Fisher’s exact test.
††Statistical analysis was performed using chi-square test.